- cafead   Jan 09, 2024 at 09:52: AM
via BioNTech (22UAy.DE) said on Tuesday it expects to return to revenue growth in 2025 when the ongoing decline in its COVID-19 vaccine business would bottom out, and that it would invest to scale up its oncology business thereafter.
article source
article source